News

ProAir Digihaler for COPD and Asthma Now Available in US

The ProAir Digihaler, a digital inhaler designed for people with asthma and chronic obstructive pulmonary disease (COPD) to monitor their inhaler usage through the use of a mobile app, is now available by prescription in the U.S. The albuterol inhaler (albuterol sulfate, 117 micrograms), developed by Teva…

COPD Seen as Potential Risk Factor for Lung and Other Cancers

Chronic obstructive pulmonary disease (COPD) appears to be a risk factor for lung cancer, liver cancer, and colorectal cancer, regardless of smoking status, a data study from Korea reported. The study, “Cancer development in patients with COPD: a retrospective analysis of the National Health Insurance Service-National…

Undersized Airways May Explain Why Some Nonsmokers Develop COPD

Having small airways compared to lung size may contribute to the development of chronic obstructive pulmonary disease (COPD) in many non-smokers, a retrospective study has found. The finding broadens understanding of the risk factors involved in COPD, say  Columbia University Irving Medical Center researchers, whose work, “Association of Dysanapsis…

Lung Denervation System Named FDA Breakthrough Device

Nuvaira‘s Lung Denervation System, under clinical investigation for its use in treating chronic obstructive pulmonary disease (COPD), has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). This designation is given to devices that have the potential to substantially improve the…

MUSC Resumes Clinical Trial Testing Targeted Lung Denervation

Following a stop due to the COVID-19 pandemic, the Medical University of South Carolina (MUSC) has become the first medical center to restart the AIRFLOW-3 clinical trial, which is testing a procedure called targeted lung denervation as a potential therapy for chronic obstructive pulmonary disease (COPD). “We’re…